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Take Home Message: P. aeruginosa is infrequent in CAP patients. Specific risk factors should be assessed 
when choosing antibiotics for CAP 
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ABSTRACT  
Pseudomonas aeruginosa is a challenging bacterium to treat due to its intrinsic antibiotic resistance to the most 
frequently used antibiotics in patients with community-acquired pneumonia (CAP). Data about the global 
burden and risk factors associated with P. aeruginosa-CAP are limited. We assessed the multinational burden 
and specific risk factors associated with P. aeruginosa-CAP. 
 
We enrolled 3,193 patients in 54 countries with confirmed diagnosis of CAP that underwent microbiological 
testing at admission. Prevalence was calculated according to the identification of P. aeruginosa. Logistic 
regression analysis was used to identify risk factors for antibiotic-susceptible and antibiotic-resistant P. 
aeruginosa-CAP. 
 
The prevalence of P. aeruginosa and antibiotic-resistant P. aeruginosa-CAP was 4.2% and 2.0%, respectively. 
The rate of P. aeruginosa CAP in patients with prior infection/colonization due to P. aeruginosa and at least 
one of the three independently associated chronic lung diseases [i.e., tracheostomy, bronchiectasis and/or very 
severe COPD]) was 67%. In contrast, the rate of P. aeruginosa CAP was 2% in patients without prior P. 
aeruginosa infection/colonization and none of the selected chronic lung diseases.  
 
The multinational prevalence of P. aeruginosa-CAP is low. The risk factors identified in this study may guide 
healthcare professionals in deciding empirical antibiotic coverage for CAP patients. 
 
  
 
INTRODUCTION 
Community acquired pneumonia (CAP) is a leading infectious cause of morbidity and mortality 
worldwide[1, 2]. Five to six billion people are diagnosed with CAP and more than 3.5 million people die 
annually secondary to CAP[1, 3]. Several viruses and bacteria cause CAP[4], but Streptococcus pneumoniae 
remains the most frequently identified bacterial pathogen in adults[5]. During the last few decades, the 
aetiology of CAP has been changing; antibiotic-resistant bacteria that were thought to be important only in 
hospital settings are now becoming more prevalent in community settings[6-8]. The evolution of this new 
pathogen ecology is threatening our capacity to treat patients with CAP[9-11].  
Pseudomonas aeruginosa, a Gram-negative bacterium, intrinsically resistant to several groups of 
antibiotics, such as β-lactams[12], has been frequently reported in CAP patients with specific health care 
associated risk factors, such as residence in a nursing home and hospitalization during the past 90 days (i.e., 
health care associated pneumonia, HCAP)[13-15]. Moreover, severe illnesses and poor clinical outcomes have 
been linked to P. aeruginosa infection in patients with CAP[15-17]. During recent years, P. aeruginosa 
circulating strains tend to have higher resistance patterns to anti-pseudomonal antibiotics, leading to infections 
that are challenging to treat[6].  
The prevalence of CAP due to P. aeruginosa varies significantly between different patient groups and 
specific risk factors for P. aeruginosa-CAP are controversial[18, 19]. Currently available data about the 
prevalence of P. aeruginosa-CAP and its resistance patterns are limited to single centre studies[15, 20] and 
studies with several methodological limitations[15, 21-23]. In a meta-analysis, Chalmers et al. reported data 
from 22 studies a prevalence ranging from 0 to 23% in different CAP populations and a pool prevalence of 
8.6% for P. aeruginosa in patients with multidrug resistant risk factors and 4% in patients without risk 
factors[24]. All were single centre/region and majority were rated as poor methodological status[24]. As a 
result, the true prevalence of P. aeruginosa-CAP globally is unknown. Currently, the risk factors associated 
with P. aeruginosa infection recognised by Infectious Diseases Society of America/ American Thoracic Society 
 (IDSA/ATS) guidelines for HCAP differ from those published in the CAP guidelines [13, 25]. Further, the 
global prevalence of multi-drug resistant (MDR) P. aeruginosa in CAP patients is unknown. Therefore, to close 
the gap regarding the global prevalence and the risk factors associated with P. aeruginosa, we designed a 
multinational, multicentre, worldwide study to determine the point prevalence of P. aeruginosa, its antibiotic 
resistance patterns, and the associated risk factors in hospitalised patients with CAP. 
 
MATERIALS AND METHODS 
Study Design 
This is a multicentre, point-prevalence study of hospitalised patients with CAP in 222 hospitals in 54 
countries. The coordinating institution for this project was the University of Texas Health San Antonio (UT 
Health) in San Antonio, Texas, USA. The UT Health Institutional Review Board approved the project to collect 
data and serve as a coordinating institution for the study (IRB# HSC20150184E). Study sites had to comply 
with local and national research regulations to participate in the study. Electronic invitations to participate were 
sent to members of various medical professional societies representing physicians specializing in infectious 
diseases, pulmonary, critical care, and internal medicine. Additionally, first authors of previously published 
studies of MDR pathogens in CAP were sent individual invitations. This project received no funding. Subjects 
were enrolled on four randomly selected days in March, April, May, and June of 2015. Each site investigator 
selected the study days to participate in compliance with the IRB stipulations, and avoid potential patient de-
identification[26]. Due to the observational nature of the study, patient consent was not required.  
 
Study Subjects 
Inclusion criteria  
Patients ≥18 years of age hospitalised with CAP were eligible for the study. CAP had to be diagnosed 
per the current IDSA/ATS guidelines[13]: presence of new pulmonary infiltrates on thoracic imaging (chest 
radiograph, computed chest tomography, or lung ultrasound) during the initial 48 hours of hospitalization and 
≥1 of the following conditions: 1) novel or increased cough with or without sputum production and/or purulent 
 respiratory secretions; 2) fever (oral or rectal temperature ≥37.8 ° C) or hypothermia (oral or rectal temperature 
<36 ° C); 3) signs of systemic inflammation (abnormal white blood cell count [leucocytosis >10,000/cm
3
, 
bandemia >10%, leukopenia <4,000/cm
3
], procalcitonin levels above the local upper limit of normal, or 
increased C-reactive protein)[26].  
 
Exclusion criteria  
Patients were excluded from participating in the study if they had hospital-acquired pneumonia (HAP) 
or ventilator associated pneumonia (VAP)[25]. Patients without microbiological testing from either blood, 
lower respiratory tract cultures, or sputum collected within 24 hours of hospital admission were also excluded. 
 
 
Data collection  
Data was collected and managed using REDCap™ (Research Electronic Data Capture), an electronic 
data capture tool hosted on the UT Heath San Antonio’s server. REDCap™ is a protected web-based 
application designed to collect research data[27]. Confirmation of microbiological results and all electronic data 
entry had to be completed within 7 days of study enrolment.  
 
Microbiological analysis 
Diagnostic testing, such as blood cultures and respiratory collection; and clinical care decisions were 
decided by attending physicians, not per study protocol[26]. Local microbiological testing protocols were used 
to process blood and sputum samples collected within the first 24 hours of hospitalization. If available, data on 
pleural fluid, tracheobronchial aspirate, and bronchoalveolar lavage fluid were collected. Local testing executed 
by each hospital included respiratory and blood cultures, urinary antigen and drug susceptibility testing. Local 
quality control protocols for Minimum Inhibitory Concentration (MIC) breakpoints and Clinical and Laboratory 
Standards Institute (CLSI) or the European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
standards were followed according with local regulations and protocols[28, 29].  
  
Study definitions  
Patients that required invasive respiratory and/or vasopressor support (IRVS) during initial 24 hours of 
hospitalization were categorised as IRVS+[30]. P. aeruginosa-CAP was defined as any patient with a confirmed 
diagnosis of CAP in whom P. aeruginosa was isolated in any respiratory fluid, including pleural effusion, 
sputum and/or bronchoalveolar lavage, and/or in the blood. Drug-resistant P. aeruginosa was defined when the 
isolated pathogen was resistant to ≥1 antibiotic and MDR P. aeruginosa was defined by resistance to ≥3 of the 
evaluated antibiotics. Antibiotic resistance to the following anti-pseudomonal antibiotics were evaluated: 
piperacillin/tazobactam, cefepime, ceftazidime, amikacin, gentamicin, tobramycin, levofloxacin, ciprofloxacin, 
imipenem, meropenem, doripenem, colistin and polymyxin B. 
Prior P. aeruginosa infection/colonization was defined as confirmed infection/colonization within the 
last year before the hospitalization, documented by the patient or available patient records. Chronic obstructive 
pulmonary disease (COPD) was defined according to FEV1/FVC ratio <0.7 and a compatible clinical history 
(including smoking history if relevant). Very severe COPD was defined as patients with COPD with evidence 
of very severe obstruction, determined by FEV1 <30% prior to hospital admission (see online supplement for 
the complete study dictionary). Site investigators were given these definitions in the study protocol manual and 
study dictionary prior to starting data collection[26]. 
 
Statistical analysis  
The prevalence of P. aeruginosa as microbiological aetiology of CAP (i.e., P. aeruginosa-CAP) was 
calculated based on the counts of P. aeruginosa isolates divided by the study cohort (i.e., CAP patients with 
microbiological test done), and is expressed as percentages. Chi-squared tests were used to compare categorical 
variables, which were expressed as counts and percentages. Continuous variables are presented as medians with 
interquartile ranges (IQR) and nonparametric Mann-Whitney U test was used to compare them. To assess the 
relationship between CAP due to P. aeruginosa and 67 demographic, clinical, epidemiological, and treatment 
variables, stepwise logistic regression model was executed. P-value<0.05 was defined as statistically significant. 
 Tableau desktop, professional edition for Mac, was used to generate prevalence maps. All statistical analyses 
were performed with IBM SPSS, Statistics for Mac, version 22.0, Armonk, NY: IBM Corp. 
 
RESULTS 
A total of 3,193 patients were recruited during four study days from 222 hospitals in 54 countries (1,877 
[58.8%] males, median [IQR] age: 68 [54-80] years). The demographics, risk factors, comorbidities, severity of 
illness, and chronic treatments are reported in Table 1. Among the 6 continents, most patients were recruited 
from Europe (1,941 [60.8%]), followed by North America (484 [15.2%]), Asia (405 [12.7%]), South America 
(203 [6.4%]), Africa (128 [4.0%]) and Oceania (32 [1.0%]). Microbiological cultures were obtained from blood 
(2,211 [69.2%]), sputum (1,630 [51.0%]), and bronchoalveolar lavage (311 [9.7%]). At least one pathogen was 
identified in 1,173 patients (36.7%), Figure e1. Tables 2 and e1 display the prevalence of P. aeruginosa-CAP 
and antibiotic-resistant P. aeruginosa-CAP per continents and countries. 
 
Prevalence of Pseudomonas aeruginosa-CAP  
P. aeruginosa-CAP was identified in 133 (4.2%) patients, representing 11.3 % (133/1,173) of all 
patients that had a positive culture for bacterial pathogens. The continental prevalence of P. aeruginosa-CAP 
was, 3.8% in Europe, 4.3% in North America, 5.2% in Asia, 4.9% in South America, 5.5% in Africa and 3.1% 
in Oceania, respectively (Figure 1). The prevalence of P. aeruginosa-CAP in each country, and a comparison 
between continents and countries is shown in Table 2 and e1. No statistically significant difference was found in 
the prevalence of P. aeruginosa-CAP among different continents. Croatia was the only country with statistically 
significant higher prevalence of P. aeruginosa-CAP (Table e1). 
 
Prevalence of antibiotic-resistant P. aeruginosa-CAP  
Antibiotic-resistant P. aeruginosa-CAP was identified in 64 (2.0%) patients, representing 5.4% 
(64/1,173) of all patients that had a positive culture. The continental prevalence of antibiotic-resistant P. 
aeruginosa-CAP was 1.6% in Europe, 2.5% in North America, 2.2% in Asia, 3.0% in South America, and 3.9% 
 in Africa, respectively (Figure 1). There were no patients with antibiotic-resistant P. aeruginosa-CAP identified 
in Oceania. No statistically significant difference was found in the prevalence of antibiotic-resistant P. 
aeruginosa-CAP among different continents (Table 2). 
 
Prevalence of multi-drug resistant P. aeruginosa-CAP 
MDR P. aeruginosa was identified in 33 (1.0%) patients, representing 2.8% (33/1,173) of all patients 
that had a positive culture. The continental prevalence of MDR P. aeruginosa-CAP was 0.9% in Europe, 1.2% 
in North America, 0.5% in Asia, 2% in South America, and 2.3% in Africa, respectively. There were no patients 
with MDR P. aeruginosa identified in Oceania. No statistically significant difference was found in the 
prevalence of MDR P. aeruginosa-CAP among different continents. No patients were infected with pan-drug 
resistant P. aeruginosa (i.e., resistant to > 3 groups of antibiotics and colistin) [31]. 
 
 
Risk factors 
Patient demographics and risk factors were compared among P. aeruginosa-CAP and non-P. aeruginosa 
CAP (Table 1). The risk factors independently associated with P. aeruginosa-CAP in the multivariate analysis 
were prior pseudomonas infection/colonization (OR: 16.10 95% CI: 9.48, 27.35), prior tracheostomy (OR: 6.50, 
95% CI: 2.61, 16.19), bronchiectasis (OR: 2.88, 95% CI: 1.65, 5.05), IRVS (OR: 2.33 95% CI: 1.44, 3.78) and 
very severe COPD (OR: 2.76 95% CI: 1.25, 6.06) (Table 3, Figure e2). Moreover, the risk factors associated 
with antibiotic-resistant P. aeruginosa-CAP were prior pseudomonas infection/colonization (OR: 17.29, 95% 
CI: 9.95, 33.42), tracheostomy (OR: 5.55, 95% CI: 1.73, 17.80) and IRVS (OR: 3.12, 95% CI: 1.63, 5.97). The 
risk factors found to be only statistically significant in the bivariate analysis were: COPD, coronary artery 
disease, inhaled corticosteroid use, indwelling catheter, and lower respiratory tract infection/ER 
visits/Hospitalisations/antibiotic treatments during the last 12 months (Table e3). Table 3 shows all the risk 
factors that had a statistically significant association with the different antibiotic resistance patterns 
(multivariate analyses are presented in Tables e2).  
 Figure 2 emphasizes the importance of the prevalence of P. aeruginosa-CAP, either one of the two main 
cluster of risk factors were tested among all the patients hospitalised with CAP or after stratifications based on 
the requirement of IRVS. Among all the patients with CAP, only 11% had risk factors (previously 
infected/colonization by pseudomonas and had chronic lung diseases [i.e., tracheostomy, bronchiectasis and/or 
very severe COPD]). The lack of these two sets of risk factors (i.e., previously infected/colonization by 
pseudomonas and tracheostomy, bronchiectasis and/or very severe COPD based on FEV1) confirms that only 2-
6% of patients might still be affected, independent of the need of IRVS. The sensitivity, specificity, 
positive/negative predictive values and positive/negative likelihood ratios of these risk factors are presented in 
table e3.  
 
DISCUSSION 
This multinational point-prevalence study found a low prevalence of P. aeruginosa among hospitalised 
patients with CAP. Only 4.2%, 2.0% and 1.0% of hospitalised patients had CAP due to P. aeruginosa, 
antibiotic-resistant P. aeruginosa, or multidrug-resistant (MDR) P. aeruginosa, respectively. No patients were 
identified with pan-drug resistant P. aeruginosa. There was no statistically significant difference in prevalence 
rates between different continents. Croatia was the only country with statistically significant higher P. 
aeruginosa-CAP prevalence. Prior pseudomonas infection/colonization, tracheostomy, bronchiectasis, IRVS, 
and very severe COPD were independently associated with P. aeruginosa-CAP. Moreover, patients admitted 
with CAP with a past medical history of pseudomonas infection/colonization or chronic lung diseases (i.e., 
tracheostomy, bronchiectasis and/or very severe COPD) had a higher risk of being infected with antibiotic-
resistant P. aeruginosa. 
Deciding empirical treatment for CAP patients has become challenging due to the emerging prevalence 
of drug-resistant bacteria, such as P. aeruginosa[6]. In a large retrospective study of culture positive patients in 
the United States, Kollef et al. reported a 19% prevalence of P. aeruginosa in hospitalised patients with 
CAP[15]. In a prospective cohort study in Europe, Chalmers et al. reported a 0.7% prevalence of P. aeruginosa 
among all patients enrolled with CAP and 2.2% among those with positive cultures[32]. Recently, Jain et al. 
 found P. aeruginosa in 0.4% of patients with CAP in a prospective cohort study in the United States and 1% 
among the patients with culture positive pneumonia[5]. We found the multinational point prevalence of P. 
aeruginosa as the causative pathogen of CAP was 4.2%, which corresponds to 11.3% of patients with positive 
culture pneumonia. Variations in the prevalence rates reported by different studies may be explained by 
differences in study design, especially the denominator used to calculate the prevalence rates[26]. However, 
these newly reported prevalence rates of P. aeruginosa–CAP are lower than prior reports[13-15], suggesting 
that only a small subgroup of patients may require empiric anti-pseudomonal antibiotic coverage. 
The IDSA/ATS CAP guidelines recommend an antipseudomonal β-lactam antibiotic plus a 
fluoroquinolone or aminoglycoside in patients with risk factors for P. aeruginosa-CAP[13]. Dual antibiotic 
coverage has been recommended for HCAP, HAP, or VAP, where multidrug resistant pseudomonas is thought 
to be an important problem[25]. Our results challenge this approach, by showing that the worldwide prevalence 
of MDR P. aeruginosa in patients with CAP is very low (1% or 3% among culture positive pneumonia 
patients). Our results are consistent with the evidence from Spain by Cilloniz et al. who reported a prevalence of 
multidrug-resistant P. aeruginosa of 1.1% in a prospective cohort study of culture positive CAP patients[33]. 
Therefore, the recommended use of double antipseudomonal empirical coverage overestimates the actual rates 
of multidrug-resistant P. aeruginosa compared to what it is found in infections acquired in hospital settings, 
where the resistance rates seems to be higher than in patients coming from the community. However, it is 
suggested that patients critically ill with septic shock due to pneumonia should receive empiric double 
antipseudomonal coverage[25]. 
Several researchers have hypothesised that studies assessing the prevalence of pathogens responsible for 
CAP are difficult to generalize because these studies are conducted in different environments (i.e., single 
hospital, regional, country or continent) with specific differences in healthcare delivery, including antibiotic 
availability and policies for antimicrobial use[19, 21, 23, 34]. In our study, we found that the prevalence of P. 
aeruginosa-CAP was not significantly different between participating centres representing different continents. 
In contrast, Croatia was the only country that had statistically significant higher P. aeruginosa-CAP prevalence. 
This study is novel by enrolling patients in a large number of centres representing more than 50 countries from 
 all over the world to identify the prevalence of P. aeruginosa in CAP patients.   
In general, many hospitalised patients receive initial empiric anti-pseudomonal coverage while waiting 
48-72 hours for specific pathogen identification and antibiotic susceptibilities[1, 3]. This practice has increased 
the use of broad-spectrum antibiotic agents and promoted antibiotic overuse with the risk of inducing 
antimicrobial resistance[11, 26]. Additionally, the delay between initial diagnosis and availability of antibiotic 
susceptibilities could negatively affect outcomes in patients with CAP due to inappropriate antibiotic 
coverage[13]. Therefore, initiation of empiric anti-pseudomonal coverage should be based on the likelihood that 
a pathogen circulates in the affected community and the presence of specific risk factors for P. aeruginosa-
CAP[6, 13, 25]. In this regard, the risk factors listed in the IDSA/ATS pneumonia guidelines for P. aeruginosa-
CAP are ICU admission, structural lung diseases, such as bronchiectasis, or COPD with multiple 
exacerbations[13]. Several risk factors have been reported for P. aeruginosa-CAP during the last few 
decades[6], but these previously reported risk factors (e.g., heart failure, tube feeding[35], etc.) were statistically 
significant in the bivariate analysis of our study, but not in the multivariable analysis. In contrast, we found that 
prior pseudomonas infection/colonization, prior tracheostomy, bronchiectasis, IRVS, and very severe COPD 
(FEV1 ≤30%) were independently associated with P. aeruginosa-CAP. These findings support the 
recommendation to consider these risk factors for empiric anti-pseudomonal antibiotics in patients with severe 
pulmonary diseases; but not in all patients with structural lung diseases. More importantly, patients with 
previous P. aeruginosa infection/colonization are at highest risk for P. aeruginosa-CAP and could benefit from 
empiric anti-pseudomonal antibiotic coverage, regardless of disease severity. Using these specific risk factors 
differs from the approach recommended by the IDSA/ATS guidelines and may help prevent overuse of anti-
pseudomonal antibiotics in patients with CAP. More importantly antimicrobial stewardship programs that 
attempt to minimize the use of anti-pseudomonal coverage among patients without the specific pseudomonas 
risk factors may help prevent adverse events and overuse of unnecessary antimicrobial therapies. 
This point prevalence study has some limitations. First, we were not able to determine clinical outcomes 
due to the study design. However, to determine prevalence rates and identify risk factors, point prevalence 
studies are ideal because they generate large sample sizes and gather generalizable data. Second, 
 microbiological samples were not collected to do centralised antibiotic susceptibility testing due to the 
experimental design and feasibility. Nevertheless, laboratories at study sites were encouraged to follow the 
CLSI or EUCAST guidelines to determine antibiotic resistance[28, 29]. Third, microbiological diagnosis of 
patients with CAP could be confounded by other pathogens colonizing the respiratory tract; however, in our 
study we only reported pathogens with representative growth according to current clinical guidelines for CAP. 
Fourth, infections other than pneumonia are possible, but less likely to present in patients with clinical signs and 
symptoms and radiological confirmation of CAP. Fifth, quality assessments were not performed because all 
data gathered were de-identifiable; however, all local investigators were instructed on how to enrol patients and 
how to use the data collection platform as described in the study protocol, data dictionary and the instructional 
video. Sixth, cystic fibrosis (CF) is a frequent cause of chronic P. aeruginosa colonization, although the 
majority of patients with CF might be included in the bronchiectasis group, CF was not directly recorded in our 
study. Finally, the empiric selection of antibiotics and diagnostic approach was performed according to the 
health care provider and it was not according to pre-specified criteria. 
In conclusion, this multinational, point prevalence study found that the burden of P. aeruginosa, 
antibiotic-resistant P. aeruginosa, and multidrug-resistant P. aeruginosa as the etiologic pathogen of CAP is 
low (less than 5%). We identified five risk factors associated with P. aeruginosa-CAP: prior pseudomonas 
infection/colonization, tracheostomy, bronchiectasis, IRVS, and very severe COPD. These risk factors could 
serve to guide empiric anti-pseudomonal antibiotic treatment. Absence of these specific risk factors suggests 
that the empiric antibiotic treatment recommended for CAP patients will cover the most likely prevalent 
bacterial pathogens. Empiric anti-pseudomonal coverage should be reserved for a small subgroup of well- 
defined patients with a past medical history of pseudomonas infection/colonization and severe lung diseases 
(i.e., prior tracheostomy, bronchiectasis and/or very severe COPD), regardless of disease severity. Importantly, 
not all patients with chronic pulmonary diseases would require empiric antipseudomonal coverage for CAP.  
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TABLES 
Table 1. Characteristics of patients with Pseudomonas aeruginosa community-acquired pneumonia (CAP) vs 
non-P. aeruginosa-CAP.  
 
 
 
 
Variables 
 
CAP 
 
n=3,193 
n (%) 
 
P. aeruginosa CAP 
 
n= 133 
n (%) 
No- 
P. aeruginosa CAP 
 
n= 3,060 
n (%) 
 
 
p 
value 
 
 
Demographic characteristics, n (%) 
Age, median (IQR) years 68 (54, 80) 64.36 (52.5,78.5) 65.01 (54, 80) 0.748 
Male 1,877 (58.8) 79 (59.4) 1,798 (58.8) 0.883 
Underweight 150/2,055 
(7.3) 
9/89 (10.1) 141/1,966 (7.2) 0.297 
Obesity 510 (16) 17 (12.8) 493 (16.1) 0.305 
 
Respiratory past medical history, n (%) 
Active lung cancer 92 (2.9) 5 (3.8) 87 (2.8) 0.536 
Asthma 234 (7.3) 8 (6) 226 (7.4) 0.553 
Bronchiectasis 168 (5.3) 31 (23.3) 137 (4.5) <0.001 
Chronic aspiration 218 (6.8) 15 (11.3) 203 (6.6) 0.038 
COPD 834 (26.1) 57 (42.9) 777 (25.4) <0.001 
     Very severe COPD (FEV1 ≤30%) 90 (2.8) 16 (12.0) 74 (2.4) <0.001 
Current/former smoker 1,114 (34.9) 46 (34.6) 1,068 (34.9) 0.940 
Interstitial lung disease 91 (2.8) 6 (4.5) 85 (2.8) 0.240 
Obstructive sleep apnoea 123 (3.9) 6 (4.5) 117 (3.8) 0.687 
Oxygen therapy at home 208 (6.5) 26 (19.5) 182 (5.9) <0.001 
Lung transplantation 7 (0.2) 1 (0.8) 6 (0.2) 0.180 
Tracheostomy 50 (1.6) 15 (11.3) 35 (1.1) <0.001 
 
Cardiovascular past medical history, n (%) 
Arrhythmia 455 (14.2) 20 (15) 435 (14.2) 0.791 
Coronary artery disease 526 (16.5) 33 (24.8) 493 (16.1) 0.008 
Heart failure 418 (13.1) 25 (18.8) 393 (12.8) 0.046 
Hypertension 1,444 (45.2) 62 (46.6) 1,382 (45.2) 0.742 
Stroke 250 (7.8) 13 (5.2) 237 (7.7) 0.394 
 
Chronic medications, n (%) 
Inhaled corticosteroids use 544 (17) 48 (36.1) 496 (16.2) <0.001 
 Proton pump inhibitor use 907 (28.4) 58 (6.4) 849 (27.7) <0.001 
Statins use 670 (21) 37 (27.8) 633 (20.7) 0.048 
Steroids use 268 (8.4) 21 (15.8) 268 (8.4) 0.002 
 
Chronic interventions, n (%) 
Enteric tube feeding 48 (1.5) 8 (6) 40 (1.3) <0.001 
Haemodialysis 51 (1.6) 4 (3) 47 (1.5) 0.185 
Indwelling catheter 67 (2.1) 11 (8.3) 56 (1.8) <0.001 
 
Immunosuppressive conditions, n (%) 
Active solid tumour 245 (7.7) 11 (4.5) 234 (7.6) 0.791 
AIDS 57 (1.8) 1 (0.8) 56 (1.8) 0.358 
Aplastic anaemia 13 (0.4) 0 (0) 13 (0.4) 0.451 
Asplenia 12 (0.4) 0 (0) 12 (0.4) 0.469 
Biological drug use 35 (1.1) 3 (2.3) 32 (1) 0.190 
Chemotherapy in the last 3 months 134 (4.2) 4 (3) 130 (4.2) 0.485 
Haematological malignancy 150 (4.70) 3 (2.3) 147 (4.8) 0.174 
HIV infection 107 (3.4) 3 (2.3) 104 (3.4) 0.473 
Immunocompromised patients 623 (19.5) 28 (21.1) 595 (19.4) 0.647 
Neutropenia 44 (1.4) 1 (0.8) 43 (1.4) 0.527 
Other immunosuppressive condition 125 (3.9) 11 (8.3) 114 (3.7) 0.008 
 
Other chronic medical conditions, n (%) 
Chronic renal failure 349 (10.9) 15 (11.3) 334 (10.9) 0.895 
Dementia 333 (10.4) 14 (10.5) 319 (10.4) 0.970 
Diabetes mellitus 681 (21.3) 28 (4.1) 653 (21.3) 0.937 
Liver disease 129 (4) 4 (3) 125 (4.1) 0.537 
Malnutrition 289 (9.1) 20 (15) 269 (8.8) 0.014 
Mental illness 220 (0.726) 10 (7.5) 210 (6.9) 0.770 
Prosthetic material 100 (3.1) 2 (1.5) 98 (3.2) 0.271 
Recurrent skin infections 55 (1.7) 4 (3.0)  51 (1.7) 0.245 
 
Other non-medical conditions, n (%) 
Bedridden 353 (11.1) 28 (21.1) 325 (92.1) <0.001 
Contact sport 5 (0.2) 0 (0) 5 (0.2) 0.641 
Healthcare worker 44 (1.4) 4 (3) 40 (1.3) 0.100 
Homeless 31 (1) 0 (0) 31 (1) 0.243 
Injection of illicit drugs 37 (1.2) 1 (0.8) 36 (1.2) 0.654 
 Living in crowded conditions 671 (21) 24 (18) 647 (21.1) 0.391 
Nursing home resident 258 (8.1) 18 (13.5) 240 (7.8) 0.018 
Worker in livestock meat industry 29 (0.9) 0 (0) 29 (0.9) 0.259 
 
Previous infections/colonization, n (%) 
Prior MRSA infection/colonization 81 (2.5) 10 (7.5) 71 (2.3) <0.001 
Prior ESBL-producing bacterial infection 54 (1.7) 5 (3.8) 49 (1.6) 0.059 
Prior Pseudomonas aeruginosa infection/colonization 96 (3) 44 (33.1) 52 (1.7) <0.001 
 
Prior healthcare exposure, n (%) 
Antibiotic infusion at home during the last 12 months 140 (4.4) 12 (9) 128 (4.2) 0.008 
Emergency room admission in the last 12 months 972 (30.4) 63 (47.4) 909 (29.7) <0.001 
Hospitalizations during the last 12 months 1026 (32.1) 70 (52.6) 956 (31.2) <0.001 
IV antibiotics during the last 12 months 812 (25.4) 64 (48.1) 748 (24.4) <0.001 
LRTI in the last 12months 928 (29.1) 66 (49.6) 862 (28.5) <0.001 
Oral antibiotics during the last 12 months 1219 (38.2) 77 (57.9) 1142 (37.3) <0.001 
 
Pneumonia severity, n (%) 
Invasive respiratory or vasopressor support (IRVS) 404 (12.7) 34 (25.6) 370 (12.1) <0.001 
ICU admission 599 (18.8) 43 (32.3) 556 (18.2) <0.001 
Non-invasive mechanical ventilation 334 (10.5) 15 (11.3) 319 (10.4) 0.753 
CAP; Community-acquired pneumonia, MRSA; Methicillin resistant Staphylococcus aureus, COPD; Chronic obstructive pulmonary 
disease, FEV1; Forced expiratory volume during the first second, CAD; Coronary artery disease, ESBL; extended-spectrum beta-
lactamases, LRTI; lower respiratory tract infections 
 
 
 
 
 
  
Table 2. Prevalence of antibiotic-resistant Pseudomonas aeruginosa-Community-acquired pneumonia (CAP) 
and antibiotic-resistant P. aeruginosa-CAP in participating centres representing different continents. 
  
  
CAP patients  
n=3,193  
Continent  
  
Rest of the world 
  
OR (95% CI)  p 
value  
%  n  %  n  
  
Pseudomonas aeruginosa-CAP 
Global 4.2 133/3193 . . . . 
       Africa 5.5 7/128 4.1 126/3065 1.34 (0.61, 2.95) 0.57 
       Asia 5.2 21/405 4.0 112/2788 1.30 (0.81, 2.10) 0.27 
       Europe 3.8 73/1941 4.8 60/1252 0.77 (0.54, 1.10) 0.15 
       North America 4.3 21/484 4.1 112/2,709 1.0 (0.65, 1.69) 0.83 
       Oceania 3.1 1/32 4.2 132/3161 0.74 (0.10, 5.46) 0.76 
       South America 4.9 10/203 4.1 123/2990 1.20 (0.62, 2.33) 0.57 
 
Antibiotic resistant Pseudomonas aeruginosa-CAP 
Global   2  64/3193  .  .  .  .  
       Africa  3.9  5/128  1.9  59/3065  2.071 (0.817, 5.252)  0.125  
       Asia  2.2  9/405  2  55/2788  1.129 (0.554, 2.303)  0.738  
       Europe  1.6  32/1941  2.6  32/1252  0.639 (0.389, 1.049)  0.076  
       North America  2.5  12/484  1.9  52/2709  0.770 (0.408, 1.453)  0.420  
       Oceania  0  0/32  2  64/3161  .  0.416  
       South America  3  6/203  1.9  58/2990  1.540 (0.656, 3.612)  0.321  
 
Multi-drug resistant Pseudomonas aeruginosa-CAP (>3 antibiotics groups) 
Global   1.0  33/3193  .  .  .  .  
       Africa  2.3  3/128  1  30/3065  2.428 (0.731, 8.063)  0.135  
       Asia  0.5  2/405  1.1  31/2788  0.441 (0.105, 1.851)  0.250  
       Europe  0.9  18/1941  1.2  15/1252  0.772 (0.388, 1.537)  0.460  
       North America  1.2  6/484  1  27/2709  1.247 (0.512, 3.036)   0.626  
       Oceania  0  0/32  1  33/3161  .  0.561  
       South America  2  4/203  1  29/2990  2.052 (0.714, 5.895)  0.173  
 
Carbapenem resistant Pseudomonas aeruginosa-CAP 
Global   1.1  34/3193  .  .  .  .  
       Africa  1.6  2/128  1.0  32/3065  1.504 (0.357, 6.348) 0.576  
       Asia  0.7  3/405  1.1  31/2788  0.664 (0.202, 2.181) 0.496  
       Europe  0.9  18/1941  1.3  16/1252  0.723 (0.367, 1.423) 0.346  
       North America  1.7  8/484  1.0  26/2709  1.734 (0.781, 3.854) 0.171  
       Oceania  0  0/32  1.1  34/3161  . 0.555  
       South America  1.5  3/203  1.0  31/2990  1.432 (0.434, 4.724) 0.554  
 
Colistin resistant Pseudomonas aeruginosa-CAP 
Global   0.4  12/3193  .  .  .  .  
       Africa  0  0/128  0.4  12/3065  .  0.478  
       Asia  0.7  3/405  0.3  9/2788  2.304 (0.621, 8.547)  0.199  
       Europe  0.4  7/1941  0.4  5/1252  0.903 (0.286, 2.850)  0.861  
       North America  0  0/484  0.4  12/2709  .  0.142  
       Oceania  3.1  1/32  0.3  11/3161  9.238 (1.157, 73.754)  0.011  
       South America  0.5  1/203  0.4  11/2990  1.341 (0.172, 10.436)  0.779  
 Table 3. Multivariate analysis of risk factors for Pseudomonas aeruginosa-Community-acquired pneumonia (CAP), antibiotic resistant (AR) P. 
aeruginosa-CAP, multidrug-resistant (MDR) P. aeruginosa-CAP, and specific antibiotic resistance patterns. 
 Prior P. aeruginosa IRVS Tracheostomy Bronchiectasis COPD Very severe COPD 
 
P. aeruginosa-CAP, n=133 
 
16.10 (9.48-27.35) 
 
2.33 (1.44-3.78) 
 
6.50 (2.61-16.19) 
 
2.88 (1.65-5.05) 
 
. 
 
2.76 (1.25-6.06) 
 
AR P. aeruginosa-CAP, n=64 
 
17.29 (9.95-33.42) 
 
3.12 (1.63-5.97) 
 
5.55 (1.73-17.80) 
 
. 
 
. 
 
. 
    
   Anti-pseudomonal cephalosporins, n=38 
 
17.79 (7.32-43.22) 
 
. 
 
. 
 
. 
 
2.58 (1.07-6.19) 
 
. 
   Piperacillin/ Tazobactam, n=30 9.72 (3.88-24.36) 4.14 (1.75-9.81) . 3.33 (1.21-9.19) . . 
   Carbapenems, n=34 10.62 (4.26-26.45) 2.70 (1.14-6.34) 10.77 (3.09-37.52) . . . 
   Aminoglycosides, n=31 17.32 (7.21-41.61) 3.02 (1.24-7.31) . . . . 
   Quinolones, n=50 17.35 (8.28-36.38) 2.84 (1.39-5.78) 4.35 (1.21-15.60) . . . 
 
MDR P. aeruginosa- CAP, n=33 
 
12.34 (5.05-30.14) 
 
3.42 (1.47-7.97) 
 
. 
 
. 
 
2.69 (1.10-6.55) 
 
. 
IRVS, invasive respiratory or vasopressor support; MDR, multidrug resistant, COPD, chronic obstructive pulmonary disease. 
 
 
 
 FIGURE LEGENDS  
Figure 1. Prevalence of Pseudomonas aeruginosa-Community-acquired pneumonia (CAP) and 
antibiotic-resistant P. aeruginosa-CAP by continents (Panel A and Panel B).  
 
Figure 2. Prevalence of Pseudomonas aeruginosa-Community-acquired pneumonia (CAP) 
according to the relevant risk factors that include prior Pseudomonas aeruginosa (pPa) 
infection/colonization, grouped variables of severe lung diseases (LDz
3
: tracheostomy, 
bronchiectasis and very severe COPD [i.e., FEV1 <30%]) and stratified according to the need of 
invasive respiratory and/or vasopressor support (IRVS). 
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Table e1. Prevalence of Pseudomonas aeruginosa at participating centers representing different 
countries. 
  
 
 
 
Countries  
Pseudomonas aeruginosa-CAP prevalence 
n=3,193 
Continent/Country 
 
Rest of the world 
 
OR (95% CI) p value 
% n % n 
Argentina 4.0 7/175 4.2 126/3018 0.95 (0.44, 2.08) 0.91 
Bulgaria 0 0/37 4.2 133/3156 . 0.20 
Croatia 12.8 12/94 3.9 121/3099 3.60 (1.91, 6.77) <0.001 
Denmark 1.2 1/86 4.2 132/3107 0.26 (0.03, 1.91) 0.15 
France 3.2 2/63 4.2 131/3130 0.75 (0.18, 3.10) 0.59 
Germany 5.2 7/134 4.1 126/3059 1.28 (0.58, 2.80) 0.53 
Greece 3.5 3/85 4.2 130/3108 0.83 (0.26, 2.68) 0.76 
India 3.3 5/150 4.2 128/3043 0.78 (0.31, 1.94) 0.60 
Ireland 3.1 1/32 4.2 132/3161 0.74 (0.10, 5.46) 0.76 
Italy 3.7 14/381 4.2 119/2812 0.86 (0.49, 1.51) 0.60 
Moldova 0 0/31 4.2 133/3162 . 0.24 
Montenegro 0 0/1 4.2 133/3192 . 0.83 
Netherlands 4.7 2/43 4.2 131/3150 1.12 (0.26, 4.69) 0.87 
Pakistan 7.5 8/107 4.1 125/3086 1.91 (0.91, 4.02) 0.08 
Portugal 1 1/101 4.3 132/3092 0.22 (0.03, 1.62) 0.10 
Saudi Arabia 7.1 3/42 4.1 130/3151 1.78 (0.54, 5.86) 0.33 
Serbia 0 0/41 4.2 133/3152 . 0.17 
Spain 3.2 19/585 4.4 114/2608 0.73 (0.44, 1.20) 0.21 
United Kingdom 3.6 5/140 4.2 128/2053 0.84 (0.34, 2.10) 0.71 
United States 4.5 20/442 4.1 113/2751 1.10 (0.68,1.80) 0.68 
 
 
  
TABLE e2. Bivariate analyses of risk factors for Pseudomonas aeruginosa-CAP, drug-
resistance P. aeruginosa-CAP and multidrug resistance P. aeruginosa-CAP. 
Bivariate P. aeruginosa-CAP 
 
Variable 
 
Odds ratio (95% CI) 
 
p-value 
     Underweight 1.46 (0.71, 2.96) 0.30 
     Obesity 0.76 (0.45, 1.28) 0.31 
     Either current or former smoker 0.99 (0.68, 1.42) 0.94 
     Alcoholism 0.79 (0.39, 1.56) 0.49 
     COPD 2.20 (1.55, 3.14) <0.01 
     COPD with FEV1<30% 5.52 (3.12, 9.77) <0.01 
     Oxygen therapy at home 3.84 (2.44, 6.05) <0.01 
     Asthma 0.80 (0.39, 1.66) 0.55 
     Non-cystic fibrosis bronchiectasis 6.48 (4.18, 10.04) <0.01 
     Interstitial Lung Disease 1.65 (0.71, 3.86) 0.24 
     Lung transplant 3.85 (0.46, 32.26) 0.21 
     OSAS 1.19 (0.51, 2.75) 0.69 
     Chronic aspiration 1.79 (1.03, 3.12) 0.04 
     Arrhythmia 1.07 (0.66, 1.74) 0.79 
     CAD 1.72 (1.15, 2.58) <0.01 
     Heart failure 1.57 (1.00, 2.46) 0.05 
     Essential arterial hypertension 1.06 (0.75, 1.50) 0.74 
     Stroke 1.29 (0.72, 2.32) 0.39 
     HIV infection 0.66 (0.20, 2.09) 0.48 
     AIDS 0.41 (0.06, 2.96) 0.37 
     Active solid tumor 1.09 (0.58, 2.05) 0.79 
     Active lung cancer 1.33 (0.53, 3.34) 0.54 
     Hematological malignancy 0.46 (0.14, 1.45) 0.18 
     Chemotherapy in the last 3 months 0.70 (0.25, 1.92) 0.49 
     Neutropenia 0.53 (0.07, 3.89) 0.53 
     Biological drug use 2.18 (0.66, 7.22) 0.20 
     Other immunosuppressive condition 2.33 (1.22, 4.44) 0.01 
     Liver disease 0.73 (0.26, 2.00) 0.54 
     Cirrhosis  1.55 (0.55, 4.33) 0.40 
     Mental illness 1.10 (0.57, 2.13) 0.77 
     Dementia 1.01 (0.57, 1.78) 0.97 
     Diabetes mellitus 0.98 (0.64, 1.50) 0.94 
     Chronic renal failure 1.04 (0.60, 1.80) 0.90 
     Hemodialysis 1.99 (0.70, 5.60) 0.19 
     Prior mycobacterial diseases 4.254(2.30, 7.87) <0.01 
     Recurrent skin infections 1.83 (0.65, 5.14) 0.25 
     Prior MRSA infection 3.42 (1.72, 6.80) <0.01 
     Prior ESBL-producing bacterial infection 2.40 (0.94, 6.13) 0.07 
     Prior Pseudomonas aeruginosa infection/colonization  28.60 (18.18, 45.01) <0.01 
     Inhaled corticosteroids use 2.92 (2.02, 4.21) <0.01 
     Statins use 1.48 (1.00, 2.18) 0.05 
     Steroids use 2.13 (1.32, 3.46) <0.01 
     Proton pump inhibitor use 2.01 (1.42, 2.86) <0.01 
ICU admission, n (%) 2.15 (1.47, 3.13) <0.01 
Invasive mechanical ventilation, n (%) 2.36 (1.53, 3.64) <0.01 
Non-invasive mechanical ventilation, n (%) 1.09 (0.63, 1.89) 0.75 
Treatment with inotropes, n (%) 3.69 (1.41, 9.64) <0.01 
Treatment with vasopressors, n (%)  2.21 (1.33, 3.67) <0.01 
     Malnutrition 1.84 (1.12, 3.00) 0.01 
     Bedridden 2.24 (1.46, 3.46) <0.01 
     Living in crowded conditions 0.82 (0.52, 1.29) 0.39 
     Healthcare worker 2.34 (0.82, 6.64) 0.11 
     Nursing home resident 1.84 (1.10, 3.07) 0.02 
     Enteric tube feeding 4.83 (2.21, 10.54) <0.01 
     Tracheostomy 10.99 (5.84, 20.67) <0.01 
     Prosthetic material 0.46 (0.11, 1.89) 0.28 
     Indwelling catheter 4.84 (2.42, 9.46) <0.01 
     Injection of illicit drugs 0.64 (0.09, 4.67) 0.66 
     Lower respiratory tract infections during the last 12 months 2.51 (1.77, 3.56) <0.01 
     Emergency room admission during the last 12 months 2.13 (1.50, 3.02) <0.01 
     Hospitalization during the last 12 months 2.44 (1.72, 3.66) <0.01 
     Antibiotic infusion at home during the last 12 months 2.27 (1.22, 4.22) <0.01 
     IV antibiotics during the last 12 months 2.87 (2.02, 4.07) <0.01 
     Oral antibiotics during the last 12 months 3.48 (2.32, 5.22) <0.01 
 
Bivariate drug resistance Pseudomonas aeruginosa-CAP 
     Underweight 1.35 (0.474 3.82) 0.58 
     Obesity 0.86 (0.42, 1.75) 0.67 
     COPD 2.72 (1.66, 4.47) <0.01 
     COPD with FEV1<30% 3.75 (1.57, 8.93) <0.01 
     Oxygen therapy at home 5.10 (2.84, 9.15) <0.01 
     Asthma 0.84 (0.30, 2.33) 0.74 
     Non-cystic fibrosis bronchiectasis 4.39 (2.30, 8.41) <0.01 
     Interstitial Lung Disease 1.70 (0.52, 5.52) 0.38 
     OSAS 2.16 (0.85, 5.49) 0.10 
     Chronic aspiration 3.274 (1.72, 6.23) <0.01 
     Arrhythmia 1.25 (0.65, 2.42) 0.50 
     CAD 2.18 (1.27, 3.76) <0.01 
     Heart failure 1.89 (1.03, 3.45) 0.04 
     Essential arterial hypertension 1.68 (1.02, 2.77) 0.04 
     Stroke 2.23 (1.12, 4.43) 0.02 
     HIV infection 0.45 (0.06, 3.29) 0.45 
     Active solid tumor 1.25 (0.53, 2.93) 0.61 
     Active lung cancer 1.68 (0.52, 5.46) 0.39 
     Hematological malignancy 0.65 (0.16, 2.68) 0.55 
     Chemotherapy in the last 3 months 0.36 (0.05, 2.59) 0.31 
     Neutropenia 1.14 (0.15, 8.40) 0.90 
     Biological drug use 3.03 (0.71, 12.89) 0.13 
     Other immunosuppressive condition 2.12 (0.84, 5.39) 0.11 
     Liver disease 0.76 (0.18, 3.15) 0.71 
     Cirrhosis  2.47 (0.75, 8.10) 0.13 
     Mental illness 1.41 (0.60, 3.30) 0.43 
     Dementia 1.61 (0.81, 3.19) 0.17 
     Diabetes mellitus 0.94 (0.51, 1.74) 0.84 
     Chronic renal failure 1.52 (0.77, 3.02) 0.23 
     Hemodialysis 2.21 (0.48, 8.52) 0.33 
     Prior mycobacterial diseases 1.74 (0.53, 5.66) 0.36 
     Recurrent skin infections 2.91 (0.88, 9.58) 0.08 
     Prior MRSA infection 5.98 (2.75, 12.99) <0.01 
     Prior ESBL-producing bacterial infection 5.33 (2.05, 13.85) 0.01 
     Prior Pseudomonas aeruginosa infection/colonization 32.36 (18.66, 56.12) <0.01 
     Inhaled corticosteroids use 3.68 (2.22, 6.11) <0.01 
     Statins use 1.37 (0.78, 2.40) 0.27 
     Steroids use 1.81 (0.89, 3.71) 0.10 
     Proton pump inhibitor use 2.58 (1.57, 4.23) <0.01 
     Severe CAP 2.35 (1.43, 3.86) <0.01 
     Malnutrition 2.63 (1.42, 4.90) <0.01 
     Bedridden 2.53 (1.40, 4.56) <0.01 
     Living in crowded conditions 0.78 (0.40, 1.49) 0.45 
     Healthcare worker 3.70 (1.12, 12.29) 0.03 
     Nursing home resident 2.42 (1.25, 4.70) <0.01 
     Enteric tube feeding 3.37 (1.02, 11.14) 0.05 
     Tracheostomy 10.50 (4.71, 23.39) <0.01 
     Prosthetic material 0.99 (0.24, 4.14) 0.99 
     Indwelling catheter 6.28 (2.75, 14.34) <0.01 
     Lower respiratory tract infections during the last 12 months 2.83 (1.72, 4.66) <0.01 
     Emergency room admission during the last 12 months 2.33 (1.42, 3.82) <0.01 
     Hospitalization during the last 12 months 2.96 (1.79, 4.90) <0.01 
     Antibiotic infusion at home during the last 12 months 4.83 (2.46, 9.46) <0.01 
     IV antibiotics during the last 12 months 3.90 (2.36, 6.43) <0.01 
     Oral antibiotics during the last 12 months 4.05 (2.31, 7.07) <0.01 
 
 
Bivariate Multidrug Resistance Pseudomonas aeruginosa-CAP 
     Underweight 0.55 (0.07, 4.09) 0.56 
     Obesity 0.94 (0.36, 2.44) 0.90 
     Either current or former smoker 1.07 (0.52, 2.18) 0.86 
     Alcoholism 1.10 (0.33, 3.62) 0.88 
     COPD 3.45 (1.73, 6.87) <0.01 
     COPD with FEV1<30% 2.25 (0.53, 9.56) 0.27 
     Oxygen therapy at home 3.96 (1.70, 9.24) <0.01 
     Asthma 1.76 (0.61, 5.04) 0.29 
     Non-cystic fibrosis bronchiectasis 4.11 (1.67, 10.10) <0.01 
     Interstitial Lung Disease 1.07 (0.14, 7.89) 0.95 
     OSAS 2.53 (0.76, 8.42) 0.13 
     Chronic aspiration 2.47 (0.94, 6.46) 0.06 
     Arrhythmia 1.63 (0.70, 3.78) 0.25 
     CAD 2.23 (1.05, 4.71) 0.04 
     Heart failure 1.48 (0.61, 3.61) 0.39 
     Essential arterial hypertension 1.46 (0.73, 2.91) 0.28 
     Stroke 1.18 (0.36, 3.89) 0.79 
     HIV infection 0.90 (0.12, 6.65) 0.92 
     Active solid tumor 1.21 (0.36, 3.98) 0.76 
     Hematological malignancy 0.63 (0.09, 4.65) 0.65 
     Biological drug use 6.11 (1.40, 26.60) 0.02 
     Other immunosuppressive condition 2.49 (0.75, 8.27) 0.14 
     Cirrhosis  1.53 (0.21, 11.42) 0.67 
     Mental illness 1.88 (0.65, 5.40) 0.24 
     Dementia 1.19 (0.41, 3.40) 0.75 
     Diabetes mellitus 0.82 (0.34, 1.99) 0.66 
     Chronic renal failure 1.12 (0.39, 3.22) 0.83 
     Recurrent skin infections 1.80 (0.24, 13.39) 0.57 
     Prior MRSA infection 3.95 (1.18, 13.22) 0.03 
     Prior ESBL-producing bacterial infection 3.86 (0.90, 16.54) 0.07 
     Prior Pseudomonas aeruginosa infection/colonization 24.10 (11.59, 50.08) <0.01 
     Inhaled corticosteroids use 3.22 (1.59, 6.51) <0.01 
     Statins use 1.21 (0.54, 2.69) 0.64 
     Steroids use 1.09 (0.33, 3.60) 0.88 
     Proton pump inhibitor use 3.06 (1.54, 6.11) <0.01 
     Severe CAP 2.80 (1.41, 5.59) <0.01 
     Malnutrition 1.81 (0.69, 4.72) 0.23 
     Bedridden 1.80 (0.74, 4.39) 0.20 
     Living in crowded conditions 0.37 (0.11, 1.23) 0.104 
     Healthcare worker 7.61 (2.23, 25.93) <0.01 
     Nursing home resident 2.05 (0.78, 5.36) 0.14 
     Enteric tube feeding 4.37 (1.01, 18.79) 0.05 
     Tracheostomy 9.34 (3.15, 27.64) <0.01 
     Prosthetic material 2.02 (0.48, 8.54) 0.34 
     Indwelling catheter 4.84 (1.44, 16.26) <0.01 
     Lower respiratory tract infections during the last 12 months 3.36 (1.68, 6.73) <0.01 
     Emergency room admission during the last 12 months 2.17 (1.09, 4.31) 0.03 
     Hospitalization during the last 12 months 2.56 (1.29, 5.10) <0.01 
     Antibiotic infusion at home during the last 12 months 5.02 (2.04, 12.36) <0.01 
     IV antibiotics during the last 12 months 3.58 (1.79, 7.13) <0.01 
     Oral antibiotics during the last 12 months 5.18 (2.41, 11.15) <0.01 
CAD: Coronary artery disease; CAP: Community-acquired pneumonia; COPD: Chronic Obstructive 
pulmonary disease; OSAS: Obstructive sleep apnea syndrome; AIDS: Acquired Immune Deficiency 
Syndrome; HIV: Human immunodeficiency virus; FEV1: Forced expiratory volume in one second; MRSA: 
Methicillin-resistant staphylococcus aureus; ESBL: Extended-spectrum  beta-lactamase 
 
 
 
 
 
Table e3. Positive and negative predictive value of the risk factors identified for P. aeruginosa in patients with CAP (i.e., pPa: prior P. 
aeruginosa colonization or infection and LDz
3
: tracheostomy, bronchiectasis and very severe COPD); stratified by patients that 
required invasive mechanical ventilation or vasopressors (IVRS).  
 
 Sensitivity, % 
 
 
Specificity, % Positive 
likelihood ratio 
Negative 
likelihood ratio 
Positive predictive 
value, % 
Negative predictive 
value, % 
CAP 
cohort 
(n=3,193) 
pPa (+) and LDz
3 
(+) 21.0 (14.5-28.9) 99.5 (99.2-99.7) 46.0 (24.8-85.3) 0.8 (0.7-0.9) 66.7 (51.9-78.8) 96.7 (96.4-96.9) 
pPa (+) and LDz
3 
(-) 12.0 (7.0-18.8) 98.8 (98.3-99.1) 9.7 (5.5-16.9) 0.9 (0.8-0.9) 29.6 (19.4-42.4) 96.3 (96.0-96.5) 
pPa (-) and LDz
3 
(+) 19.5 (13.2-27.3) 92.8 (91.8-93.7) 2.7 (1.9-3.9) 0.9 (0.8-0.9) 10.6 (7.6-14.6) 96.4 (96.1-96.6) 
pPa (-) and LDz
3 
(-) 52.6 (43.8-61.3) 91.1 (90.0-92.1) 5.9 (4.9-7.2) 0.5 (0.4-0.6) 20.5 (17.4-23.9) 97.8 (97.4-98.1) 
IRSV – 
cohort 
(n=2,789) 
pPa (+) and LDz
3 
(+) 25.2 (17.1-35.0) 99.5 (99.2-99.7) 26.6 (29.3-109.4) 0.7 (0.7-0.8) 67.6 (51.9-80.1) 97.3 (97.9-97.6) 
pPa (+) and LDz
3 
(-) 13.1 (7.2-21.4) 98.9 (98.5-99.3) 12.2 (6.5-22.7) 0.9 (0.8-0.9) 30.9 (19.4-45.5) 96.9 (96.6-97.1) 
pPa (-) and LDz
3 
(+) 19.2 (11.9-28.3) 93.0 (92.0-94.0) 2.8 (1.8-4.2) 0.9 (0.8-1.0) 9.2 (6.2-13.5) 96.9 (96.6-97.2) 
pPa (-) and LDz
3 
(-) 57.6 (47.2-67.4) 91.5 (90.4-92.5) 6.8 (5.5-8.4) 0.5 (0.4-0.6) 20.0 (16.8-23.6) 98.3 (97.9-98.7) 
IRSV + 
cohort 
(n=404) 
pPa (+) and LDz
3 
(+) 8.8 (1.9-23.7) 99.5 (98.1-99.9) 16.32 (2.8-94.3) 0.9 (0.8-1.0) 60.0 (20.6-89.6) 92.2 (91.4-92.9) 
pPa (+) and LDz
3 
(-) 8.8 (1.9-23.7) 97.6 (95.4-98.9) 3.63 (1.0-12.8) 0.9 (0.8-1.0) 25.0 (8.6-54.0) 92.1 (91.3-92.9) 
pPa (-) and LDz
3 
(+) 20.6 (8.7-37.9) 91.1 (87.7-93.8) 2.3 (1.1-4.8) 0.9 (0.7-1.0) 17.5 (9.2-30.7) 92.6 (91.3-93.7) 
pPa (-) and LDz
3 
(-) 38.2 (22.2-56.4) 88.1 (84.4-91.2) 3.2 (1.9-5.3) 0.7 (0.5-0.9) 22.8 (15.1-33.0) 93.9 (92.2-95.3) 
All values are presented with 95% Confidence of Interval. pPa: prior Pseudomonas aeruginosa; LDz
3
: lung diseases independently associated with 
Pseudomonas aeruginosa-CAP (tracheostomy, bronchiectasis and COPD with FEV1 <30% [i.e., severe COPD]); IRVS: Invasive respiratory 
and/or vasopressor support.  
 
 
 SUPPLEMENTARY FIGURE LEGENDS  
Figure e1. Flowchart of patients hospitalized with community-acquired pneumonia (CAP) 
enrolled in the study. 
Figure e2. Multivariate analysis of the risk factors independently associated with Pseudomonas 
aeruginosa-Community-acquired pneumonia (CAP). 
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SUPPLEMENTARY DOCUMENTS  
1. Study manual. 
GLIMP STUDY MANUAL AND DEFINITIONS 
1. Male/female: checked box about the gender of the subject   
2. Health care worker: health professional in health care services (e.g.: nurse,  physicians, 
dentist, physiotherapist, etc.).   
3. Livestock/meat industry worker: employee working with domestic animals,  such as cattle, for 
home use or for profit, including production of meat and dairy  products.   
4. Nursing home resident: A patient living in a facility or institution that provides  health care 
such as rehabilitation, restorative and skilled nursing care to patients  in need of 
assistance with activities of daily living, especially for elderly people.   
5. Bedridden/Bedbound: patient confined to a bed for at least a month prior to  hospital 
admission, mainly because of a poor performance status.   
6. Community and crowded living: a setting with close contacts such as prison,  dormitories, 
shelter, barracks, etc.   
7. Previous influenza virus vaccination: influenza vaccination during the prior  and/or current 
influenza season.   
8. Previous conjugate pneumococcal vaccination: prior pneumococcal vaccination  with a 
conjugate vaccine (such as PCV7, PCV10 or PCV13).   
9. Previous polysaccharide pneumococcal vaccination: prior pneumococcal  vaccination with a 
23-valent pneumococcal polysaccharide vaccine (PPSV23).   
Section 2  
2. Low respiratory tract infections: respiratory infections including pneumonia, acute 
exacerbation of COPD and acute exacerbation of bronchiectasis.   
3. COPD Exacerbation: an event in the natural course of the COPD characterized by a worsening 
of the patient’s baseline dyspnea, cough and/or sputum beyond day-to-day variability 
sufficient to warrant a change in management.   
4. Emergency room visits: emergency room visits for any reason.   
5. Hospitalizations: hospital admission for more than 24 hours for any reason.   
6. Home antibiotic infusion therapy: intravenous antibiotic administration through a permanent 
or temporary catheter for any reason at home.   
7. Intravenous antibiotic courses: intravenous antibiotic courses for any reason.   
8. Oral antibiotic courses: antibiotic administered through the mouth for any  reason.   
Section 3  
1. Aspiration: history of previous episodes of aspiration, with or without dysphagia.   
 
2. Chronic renal failure: an estimated glomerular filtration rate < 60 mL/min/1.73m2 during 
at least six months before hospital admission.   
 
3. Chronic arrhythmia: presence of any of the following arrhythmias: atrial flutter, atrial 
fibrillation, junctional supraventricular, paroxysmal supraventricular tachycardia, 
ventricular tachycardia during at least six months before hospital admission.   
 
4. Aplastic anemia: deficiency of all types of blood cells or pancytopenia (anemia, 
leukopenia and thrombocytopenia) due to failure of the bone morrow.   
 
5. HIV: human immunodeficiency virus infection, regardless of the number of CD4+ 
lymphocytes/mm3.   
 
6. Asthma: prior clinical diagnosis of bronchial asthma during at least six months before 
hospital admission.   
 
7. Chronic hemodialysis: need of hemodialysis during at least six months before hospital 
admission.   
 
8. Mental illness: any psychiatric disorder including depression and excluding dementia 
during at least six months before hospital admission.   
 
9. Asplenia: absence of the spleen (anatomical asplenia) or presence of a spleen that does 
not function (functional asplenia).   
 
10. AIDS: either human immunodeficiency virus infection with < 200 CD4+ 
lymphocytes/mm3 or acquired immune deficiency syndrome (AIDS)-defining conditions.  
 
11. Heart failure: A clinical diagnosis of left ventricular failure of congestive cardiac failure 
for at least six months before hospital admission.  
 
12. Bronchiectasis: presence of abnormal dilatation of bronchi on computed tomography scan 
of the thorax.  
 
13. Dementia: impairment of at least two brain functions, including memory, thinking, 
judgment, language and social abilities such as performing daily activities during at least 
six months before hospital admission. 
 
14. Active solid tumor: any active solid tumor, excluding lung cancer and hematological 
malignancy before hospital admission.  
 
15. Stroke: either ischemic and/or hemorrhagic stroke before hospital admission.   
 
16. Homeless: people without a regular home before hospital admission.   
 
17. Injectable drugs: any current use of injectable drugs (e.g. cocaine, heroin, etc.)  before 
hospital admission.   
 
18. Myocardial infarction: a past medical history consistent with acute myocardial 
 infarction.   
 19. Interstitial lung diseases: any diffuse parenchymal lung disease before hospital 
 admission (e.g. idiopathic pulmonary fibrosis [IPF], nonspecific interstitial  pneumonia 
[NSIP], etc.).   
 
20. Lung transplantation: having one or both lungs transplanted.   
 
21. Alcoholism: chronic condition characterized by excessive use of alcohol on a  regular 
basis.   
 
22. Coronary artery disease: history of coronary artery disease, including angina  (stable or 
unstable), before hospital admission.   
 
23. Neutropenia: less than 500 neutrophils/dL on the complete blood count before  hospital 
admission.   
 
24. Obesity: body mass index (BMI) ≥ 30. BMI calculation: weight (Kg) / (height  (m))2.   
 
25. Hematological malignancy: any active hematological malignancy (including lymphoma, 
acute or chronic leukemia and multiple myeloma) before hospital admission.  
 
26. Contact sport: currently participating in any sport requiring skin-to-skin contact before 
hospital admission (e.g. rugby, wrestling, soccer, basketball, etc.).  
 
27. Chronic liver disease: any liver disease excluding cirrhosis during at least six months 
before hospital admission (e.g. chronic viral hepatitis, nonalcoholic hepatitis, etc.).   
 
28. Chronic biological drugs: use of biological drugs, including anti-cancer therapies such as 
trastuzumab and therapies for autoimmune diseases such as anti-TNFα, during at least six 
months before hospital admission.   
 
29. Recurrent skin infections: more than one skin infection during one year before hospital 
admission (e.g. skin abscess, folliculitis, chronic skin ulceration).   
 
30. Chronic inhaled steroids: use of any kind of inhaled steroids, such as beclomethasone, 
budesonide, fluticasone, or mometasone, on a regular basis (at least 3 times a week) 
during at least six months before hospital admission.  
 
31. Prosthetic material: any prior implantation of prosthetic material, including cardiac 
valves or orthopedic replacement, excluding dental implants.  
 
32. Cirrhosis: Clinical diagnosis of features consistent with hepatic fibrosis and nodular 
regeneration during at least six months before hospital admission.  
 
33. Chronic indwelling catheter: need to maintain an indwelling catheter (including bladder 
catheter and central venous catheter) during at least six months before hospital admission.  
 
34. Diabetes Mellitus: diagnosis of diabetes mellitus, whether type I or Type II before 
hospital admission.  
 
35. Chronic steroids: steroid treatment > 10 mg of prednisone/daily or equivalent during at 
least three months before hospital admission.   
 
36. Prior mycobacteria disease: any past medical history of mycobacterial infection or 
colonization including Mycobacterium tuberculosis complex and non- tuberculous 
mycobacteria.   
 
37. Malnutrition: chronic poor nutrition identified through laboratories (e.g. low levels of 
plasma protein), physical exam (e.g. low BMI) or medical history before hospital 
admission. 
38. COPD: chronic obstructive pulmonary disease defined according to FEV1/FVC ratio 
<0.7 and a compatible clinical history (including smoking history if relevant)   
39. Hypertension: chronic systolic blood pressure ≥ 140 mmHg and/or diastolic blood 
pressure ≥ 90 mmHg or chronic need of any antihypertensive treatment to maintain 
systemic arterial pressure below these levels during at least six months before hospital 
admission.  
 
40. Other immunosuppression: any immunosuppressive state including congenital/genetic 
immunosuppression and immunosuppressive therapy due to hematological/solid organ 
transplantation other than lung (excluding hematological malignancies, asplenia, aplastic 
anemia, neutropenia, chronic biological drugs, chronic steroid treatment, HIV/AIDS and 
chemotherapy) during at least six months before hospital admission.  
 
41. Chemotherapy in the prior 3 months: any chemotherapy in the previous 3 months before 
hospital admission.  
 
42. Enteral tube feedings: chronic feeding through a tube directly into the gastrointestinal 
tract (including nasogastric tube and percutaneous endoscopic gastrostomy tube –PEG-) 
before hospital admission.  
 
43. FEV1 <30%: Forced Expiratory Volume in the 1st second < 30% of predicted reference 
values calculated according to gender, age, height and weight.  
 
44. Chronic use of proton pump inhibitors: any proton pump inhibitors use on a regular basis 
during at least six months before hospital admission.  
 
45. Home oxygen therapy: chronic/long term need of oxygen supply to correct hypoxia due 
to cardiac and/or pulmonary diseases (even at a stable state of the disease) before hospital 
admission.  
 
46. Chronic statin use: any statin uses on a regular basis during at least six months before 
hospital admission.  
Section 4  
Severity of the disease within 24 hours after hospital admission, including:  
1. Admission to an Intensive Care Unit (ICU) or a High-dependency unit (HDU, also 
known as respiratory intensive care unit or semi-intensive care unit or  progressive care 
unit) within the first 24 hours after hospital admission.   
 
2. Non-invasive mechanical ventilation (NIV) during the first 24 hours of hospital 
 admission.  
 3.  Invasive mechanical ventilation during the first 24 hours after hospital  admission.   
 
4. Vasopressors use, including epinephrine, norepinephrine or dopamine, within  the first 
24 hours after hospital admission.   
 
5. Inotropes use, including dobutamine, within the first 24 hours after hospital  admission. 
  
Section 5  
Please indicate if during the past year the patient was infected or colonized with one of the 
following pathogens prior to hospital admission.  
Mark if during the year prior of the current hospitalization the patient had documented infection 
due to Methicillin Resistant Staphylococcus aureus (MRSA); Pseudomonas aeruginosa or 
Extended Spectrum Beta-Lactamase producing Gram negative bacilli (ESBL).  
 
Section 6  
Please indicate all the diagnostic tests performed within 24 hours of hospital admission. This 
question refers to the tests ordered and actually performed during the first 24 hours of hospital 
admission. The answers are self-explanatory.  
Section 7  
Please indicate if a pathogen was identified (whether cultured or other test) as the possible 
responsible etiology for the patient admitted with pneumonia. In case the investigator selects the 
box YES, a series of boxes (as shown in the pdf case report form) will appear for the 
documentation UP TO 2 microorganisms:  
1 - Select the name of the pathogen   
2 - Select the source of the pathogen (select ALL that apply) - Select antibiotic 
susceptibilities (a list of pre-specified antimicrobial  resistance patterns will appear in the 
e-CRF. Please check ALL that apply).   
Section 8  
Please indicate ALL the antibiotics or antimicrobial agents administered during the first 24 
hours of admission to the hospital.  
- Select ALL THE NAMES THAT APPLY  
 
